ETOP 14-18 CHESS: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic non-small cell lung cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511134-12-00

Acronym

ETOP 14-18 CHESS

Enrollment

Registered

2024-09-19

Start date

2023-12-20

Completion date

Unknown

Last updated

2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC, synchronous oligo-metastatic

Brief summary

Progression-free survival at 1 year

Detailed description

Overall survival, Pattern of disease progression, Distant progression-free survival, Response to induction therapy, Overall response, Duration of response, Toxicity before and after surgery/radiotherapy, Symptom-specific and global quality of life

Interventions

DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival at 1 year	—

Secondary

Measure	Time frame
Overall survival, Pattern of disease progression, Distant progression-free survival, Response to induction therapy, Overall response, Duration of response, Toxicity before and after surgery/radiotherapy, Symptom-specific and global quality of life	—

Countries

Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026